126 related articles for article (PubMed ID: 31331494)
1. Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Vergote I; Coleman RL; Pignata S; Bookman MA; Marth C; Herzog TJ; Gonzalez-Martin A; Copeland LJ; ;
Gynecol Oncol; 2019 Aug; 154(2):255-258. PubMed ID: 31331494
[No Abstract] [Full Text] [Related]
2. Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Vergote I; Coleman RL; Pignata S; Bookman MA; Marth C; Herzog TJ; Gonzalez Martin A; Copeland LJ;
Int J Gynecol Cancer; 2019 Sep; 29(7):1094-1097. PubMed ID: 31320391
[No Abstract] [Full Text] [Related]
3. The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation.
Monk BJ; Coleman RL; Herzog TJ; Moore KN; O'Malley DM; Randall LM; Slomovitz BM; Eskander R; Pothuri B; Reese LL; Mannel RS; Copeland LJ
Gynecol Oncol; 2021 Jul; 162(1):203-209. PubMed ID: 33722417
[TBL] [Abstract][Full Text] [Related]
4. European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.
du Bois A; Reuss A; Pujade-Lauraine E; Pignata S; Ledermann J; Casado A; Sehouli J; Mirza M; Colombo N; Marth C; Witteveen E; Del Campo J; Calvert P; Aravantinos G; Vardar MA; van der Zee AG; Korach J; Taskiran C; Fehr M; Glasspool R; Pfisterer J; Cibula D; Vergote I;
Int J Gynecol Cancer; 2015 Sep; 25(7):1328-30. PubMed ID: 26067859
[TBL] [Abstract][Full Text] [Related]
5. Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.
Vergote I; Elser G; Votan B; Farrelly L; De Roover J; Bryce J; du Bois A;
Int J Gynecol Cancer; 2013 Sep; 23(7):1339-43. PubMed ID: 23970159
[TBL] [Abstract][Full Text] [Related]
6. Report on NRG Oncology and the GOG Foundation.
Alvarez RD
Gynecol Oncol; 2015 Oct; 139(1):3-4. PubMed ID: 26325528
[No Abstract] [Full Text] [Related]
7. European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies.
Vergote I; Pujade-Lauraine E; Pignata S; Kristensen GB; Ledermann J; Casado A; Sehouli J; Mirza M; Fossati R; Marth C; Creutzberg C; Del Campo J; Siddiqui N; Calvert P; Bamias A; Tulunay G; van der Zee AG; du Bois A;
Int J Gynecol Cancer; 2010 Apr; 20(3):476-8. PubMed ID: 20375816
[No Abstract] [Full Text] [Related]
8. Society of Gynecologic Oncology meeting highlights progress.
Jenks S
J Natl Cancer Inst; 2011 Apr; 103(7):533-4. PubMed ID: 21436060
[No Abstract] [Full Text] [Related]
9. Food and Drug Administration public hearing on the draft guidance for exception from informed consent requirements for emergency research: testimony of Novo Nordisk.
Weiskopf RB;
Acad Emerg Med; 2007 Apr; 14(4):e71-3. PubMed ID: 17322571
[No Abstract] [Full Text] [Related]
10. Conduct and reporting of clinical research.
Liu JL; Altman DG
Science; 2005 Apr; 308(5719):201-2. PubMed ID: 15821071
[No Abstract] [Full Text] [Related]
11. Harmful impact of EU clinical trials directive.
Hemminki A; Kellokumpu-Lehtinen PL
BMJ; 2006 Mar; 332(7540):501-2. PubMed ID: 16513690
[No Abstract] [Full Text] [Related]
12. European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development.
Concin N; Ray-Coquard I; Glasspool RM; Braicu E; Farrelly L; Votan B; Mirza MR; Gonzalez Martin A; Vergote I; Pignata S
Int J Gynecol Cancer; 2020 Jun; 30(6):730-734. PubMed ID: 32404377
[No Abstract] [Full Text] [Related]
13. Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
Pothuri B; Blank SV; Myers TK; Hines JF; Randall LM; O'Cearbhaill RE; Slomovitz BM; Eskander RN; Alvarez Secord A; Coleman RL; Walker JL; Monk BJ; Moore KN; O'Malley DM; Copeland LJ; Herzog TJ
Gynecol Oncol; 2023 Jul; 174():278-287. PubMed ID: 37315373
[No Abstract] [Full Text] [Related]
14. [Foreward].
Ehninger G; Overkamp F; Freund M;
Onkologie; 2013; 36 Suppl 2():1. PubMed ID: 23549029
[No Abstract] [Full Text] [Related]
15. Gynecologic Oncology Group (GOG) Report.
Alvarez RD
Gynecol Oncol; 2010 Nov; 119(2):181-2. PubMed ID: 20719372
[No Abstract] [Full Text] [Related]
16. [Clinical trials--only for the industry?].
Dale O
Tidsskr Nor Laegeforen; 2013 May; 133(10):1043. PubMed ID: 23712137
[No Abstract] [Full Text] [Related]
17. Gynecologic Oncology Group quality assurance audits: analysis and initiatives for improvement.
Blessing JA; Bialy SA; Whitney CW; Stonebraker BL; Stehman FB
Clin Trials; 2010 Aug; 7(4):390-9. PubMed ID: 20576671
[TBL] [Abstract][Full Text] [Related]
18. India's drug tests.
Padma TV
Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
[No Abstract] [Full Text] [Related]
19. Relationships between medicine and industry: approaches to the problem of conflicts of interest.
Raad R; Appelbaum PS
Annu Rev Med; 2012; 63():465-77. PubMed ID: 21888513
[TBL] [Abstract][Full Text] [Related]
20. Consistent clinical research standards benefit patients around the world.
Herring J
Nat Med; 2011 Sep; 17(9):1036. PubMed ID: 21900910
[No Abstract] [Full Text] [Related]
[Next] [New Search]
